BR112021004771A2 - Composições de ácido hialurônico-toxina clostridial - Google Patents
Composições de ácido hialurônico-toxina clostridialInfo
- Publication number
- BR112021004771A2 BR112021004771A2 BR112021004771A BR112021004771A BR112021004771A2 BR 112021004771 A2 BR112021004771 A2 BR 112021004771A2 BR 112021004771 A BR112021004771 A BR 112021004771A BR 112021004771 A BR112021004771 A BR 112021004771A BR 112021004771 A2 BR112021004771 A2 BR 112021004771A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- hyaluronic acid
- clostridial toxin
- toxin compositions
- antioxidant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862731063P | 2018-09-13 | 2018-09-13 | |
| PCT/US2019/051173 WO2020056371A1 (en) | 2018-09-13 | 2019-09-13 | Clostridial toxin-hyaluronic acid compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021004771A2 true BR112021004771A2 (pt) | 2021-11-09 |
Family
ID=68069925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021004771A BR112021004771A2 (pt) | 2018-09-13 | 2019-09-13 | Composições de ácido hialurônico-toxina clostridial |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20200108129A1 (https=) |
| EP (1) | EP3849512A1 (https=) |
| JP (2) | JP2022500426A (https=) |
| KR (2) | KR20250124258A (https=) |
| CN (1) | CN112888454A (https=) |
| AU (1) | AU2019339519A1 (https=) |
| BR (1) | BR112021004771A2 (https=) |
| CA (1) | CA3112394A1 (https=) |
| MX (2) | MX2021002992A (https=) |
| WO (1) | WO2020056371A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9480731B2 (en) * | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
| KR102480965B1 (ko) | 2016-09-13 | 2022-12-26 | 알레간 인코포레이티드 | 안정화된 비단백질 클로스트리듐 독소 조성물 |
| CN115397399B (zh) * | 2020-04-08 | 2025-06-27 | 玫帝托克斯股份有限公司 | 一种易于控制排出速度且稳定的肉毒杆菌毒素预填充式注射器剂型 |
| JP2024500416A (ja) * | 2020-12-18 | 2024-01-09 | エーティージーシー カンパニー、リミテッド | ボツリヌス毒素の液剤を長期保管するための薬学的組成物 |
| EP4615489A1 (en) | 2022-11-07 | 2025-09-17 | Allergan, Inc. | Prevention of post-operative atrial fibrillation with a botulinum toxin |
| JP2025541064A (ja) | 2022-12-15 | 2025-12-18 | メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン | ボツリヌス毒素を含む注射可能なゲルおよびその使用 |
| WO2025151741A1 (en) * | 2024-01-10 | 2025-07-17 | Brown David Donaldson | Methods of treating migraine headache or tension headache with hyaluronic acid |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4636524A (en) | 1984-12-06 | 1987-01-13 | Biomatrix, Inc. | Cross-linked gels of hyaluronic acid and products containing such gels |
| US5099013A (en) | 1985-03-12 | 1992-03-24 | Biomatrix, Inc, | Hylan preparation and method of recovery thereof from animal tissues |
| US4713448A (en) | 1985-03-12 | 1987-12-15 | Biomatrix, Inc. | Chemically modified hyaluronic acid preparation and method of recovery thereof from animal tissues |
| US5143724A (en) | 1990-07-09 | 1992-09-01 | Biomatrix, Inc. | Biocompatible viscoelastic gel slurries, their preparation and use |
| US7758872B1 (en) | 2003-02-07 | 2010-07-20 | Eric Finzi | Method of treating depression |
| ES2509872T3 (es) | 2005-03-03 | 2014-10-20 | Allergan, Inc. | Procedimientos para obtener una toxina clostrídica |
| US8137677B2 (en) * | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
| AU2016204034B2 (en) * | 2005-10-06 | 2017-12-21 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
| US9044477B2 (en) * | 2007-12-12 | 2015-06-02 | Allergan, Inc. | Botulinum toxin formulation |
| US9107815B2 (en) * | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
| KR101604515B1 (ko) | 2008-03-14 | 2016-03-17 | 알러간, 인코포레이티드 | 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정 |
| CN105833254A (zh) * | 2008-12-10 | 2016-08-10 | 阿勒根公司 | 梭菌毒素药物组合物 |
| BRPI1008940A2 (pt) | 2009-03-13 | 2020-10-27 | Allergan, Inc. | linhagem de célula clonal estabelecida suscetível à intoxicação por bont/a |
| US9480731B2 (en) * | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
| CN108463242A (zh) * | 2016-03-02 | 2018-08-28 | 梅尔兹制药公司 | 包含肉毒杆菌毒素的组合物 |
| KR102480965B1 (ko) * | 2016-09-13 | 2022-12-26 | 알레간 인코포레이티드 | 안정화된 비단백질 클로스트리듐 독소 조성물 |
-
2019
- 2019-09-13 MX MX2021002992A patent/MX2021002992A/es unknown
- 2019-09-13 BR BR112021004771A patent/BR112021004771A2/pt not_active IP Right Cessation
- 2019-09-13 US US16/571,014 patent/US20200108129A1/en not_active Abandoned
- 2019-09-13 WO PCT/US2019/051173 patent/WO2020056371A1/en not_active Ceased
- 2019-09-13 JP JP2021514022A patent/JP2022500426A/ja active Pending
- 2019-09-13 KR KR1020257026240A patent/KR20250124258A/ko active Pending
- 2019-09-13 CN CN201980069935.6A patent/CN112888454A/zh active Pending
- 2019-09-13 CA CA3112394A patent/CA3112394A1/en active Pending
- 2019-09-13 AU AU2019339519A patent/AU2019339519A1/en not_active Abandoned
- 2019-09-13 KR KR1020217010717A patent/KR20210057129A/ko not_active Ceased
- 2019-09-13 EP EP19778773.2A patent/EP3849512A1/en not_active Withdrawn
-
2021
- 2021-03-12 MX MX2024007080A patent/MX2024007080A/es unknown
-
2022
- 2022-06-30 US US17/854,334 patent/US20230158129A1/en not_active Abandoned
-
2024
- 2024-06-19 JP JP2024098708A patent/JP2024137952A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3112394A1 (en) | 2020-03-19 |
| KR20210057129A (ko) | 2021-05-20 |
| JP2022500426A (ja) | 2022-01-04 |
| WO2020056371A1 (en) | 2020-03-19 |
| EP3849512A1 (en) | 2021-07-21 |
| AU2019339519A1 (en) | 2021-05-06 |
| US20230158129A1 (en) | 2023-05-25 |
| JP2024137952A (ja) | 2024-10-07 |
| US20200108129A1 (en) | 2020-04-09 |
| CN112888454A (zh) | 2021-06-01 |
| KR20250124258A (ko) | 2025-08-19 |
| MX2021002992A (es) | 2021-11-12 |
| MX2024007080A (es) | 2024-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019004935A2 (pt) | composições de toxina clostridial não proteíca estabilizada | |
| BR112021004771A2 (pt) | Composições de ácido hialurônico-toxina clostridial | |
| EA201992772A1 (ru) | Инъецируемые препараты длительного действия, содержащие изоксазолиновое действующее вещество, способы и применение | |
| MX2018005194A (es) | Proteinas de fusion fgf21 de accion prolongada y composicion farmacuetica que comprende las mismas. | |
| CL2017001115A1 (es) | Formulación estable de proteina en solución que contiene una alta concentración de un anticuerpo anti-vegf. | |
| BR112019009113A2 (pt) | formulações de vírus adenoassociado | |
| BR112018017265A2 (pt) | compostos antiparasíticos de isoxazolina, formulações injetáveis de ação prolongada que os compreendem, métodos e utilizações dos mesmos | |
| WO2016149028A3 (en) | Epinephrine formulations | |
| MX390954B (es) | Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo. | |
| MX2017007178A (es) | Formulaciones liquidas estables de virus de vacuna. | |
| CL2019001366A1 (es) | Formulaciones tamponadas exendina (9-39). | |
| BR112015011743A2 (pt) | conservantes | |
| BR112016024020A8 (pt) | composição farmacêutica | |
| WO2016030899A8 (en) | Methods of treating amyotrophic lateral scleroses | |
| MY209656A (en) | Compositions and methods of enhancing 5-hydroxytryptophan bioavailability | |
| BR112019024750A2 (pt) | uso de glutamina sintetase no tratamento da hiperamonemia | |
| BR112022004038A2 (pt) | Composições veterinárias granulares palatáveis | |
| CR20150508A (es) | Formulaciones veterinarias estables de combinación de lactonas macrocíclicas e imidazotiazoles | |
| MX2019006775A (es) | Formulaciones de rociamiento de piretroide y método de uso de las mismas. | |
| EA201992142A1 (ru) | Фармацевтические композиции и их применения | |
| BR112018016874A2 (pt) | métodos e composições para distribuição de arilsulfatase a no sistema nervoso central (snc) | |
| BR112023006143A2 (pt) | Composição farmacêutica para prevenir ou tratar doença hepática colestática, contendo beta-lapachona como ingrediente ativo | |
| TW202615087A (zh) | 非蛋白梭菌毒素組成物 | |
| AR103636A1 (es) | Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol | |
| MX378195B (es) | Agente terapeutico para dislipidemia. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2845 DE 15-07-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |